Rollover Equity in DSO Deals: What Dentists Need to Know
Rollover equity shows up in most DSO transactions today, and it's often presented as a meaningful part of the purchase price. Understanding what it actually is — and isn't — matters before you factor it into your decision.
What Rollover Equity Actually Is
Instead of receiving 100% of the purchase price in cash, sellers roll a portion of their proceeds into equity in the DSO's holding company or parent entity. In theory, that equity grows in value as the DSO grows and eventually gets sold or recapitalized.
Vesting Schedules Can Erase Your Upside
Rollover equity is frequently subject to vesting, and cliff vesting schedules can mean losing unvested units entirely if you leave — even without cause — before a certain date. The details of "good leaver" versus "bad leaver" provisions matter enormously here.
Liquidity Is Often Years Away (Or Never)
Unlike cash at closing, rollover equity typically can't be sold until the DSO has its own liquidity event — a future recapitalization, sale, or IPO. That could be three years out, ten years out, or may not happen in a way that benefits minority equity holders at all.
Questions to Ask Before You Treat Rollover as Real Value
What triggers forfeiture of unvested equity, and under what circumstances?
Has this DSO been through a prior recapitalization, and how did minority holders fare?
What are the drag-along and tag-along rights if the DSO is sold again?
What would this deal look like if the rollover equity were valued at zero?
That last question is worth sitting with. If the cash portion of the deal alone doesn't make sense to you, rollover equity shouldn't be what tips the scale.
Comments